Trial Profile
A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 780 in Adult Subjects With Advanced Solid Tumors.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 19 Apr 2016
Price :
$35
*
At a glance
- Drugs AMG 780 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Amgen
- 13 Apr 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 03 Mar 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.